Investors should consider Novo Nordisk (NVO) as a high-conviction value play, currently trading at a significant discount with a low 9.8x P/E ratio and a 4% dividend yield. While Eli Lilly (LLY) is the current growth leader with superior triple-pathway drugs expected by 2027, NVO offers better risk-adjusted entry points as it scales manufacturing for its upcoming CagriSema and oral pill offerings. For diversified exposure to the mass-market shift in weight-loss treatments, build a "basket" of NVO, LLY, and Hims & Hers Health (HIMS) rather than buying diluted sector ETFs. Monitor NVO for potential price dips caused by geopolitical "tariff scares," which may provide attractive buying opportunities regardless of the company's strong 53% EBITDA margins. Focus on the transition from injections to oral GLP-1 pills, as this form factor is expected to drive massive adoption toward the goal of 1 in 3 Americans using these drugs by 2030.

Novo Nordisk (NVO)

The speaker views Novo Nordisk as the "value play" in the GLP-1 space. While currently perceived as being in a "valley of despair" (down significantly from its 2024 peak), its valuation metrics are considerably lower than its primary competitor, Eli Lilly.

• Product Pipeline:
  • Semaglutide: The current flagship (Ozempic/Wegovy). It is considered an "older generation" single-pathway drug compared to Lilly’s current offerings.
  • CagriSema: A dual-pathway drug currently in advanced trials. Once approved, it is expected to put Novo on equal footing with Lilly’s current top drug.
  • Oral GLP-1 (Pill): Novo’s oral version is seeing strong early numbers. The speaker suggests Novo’s pill may be superior to Lilly’s version (Orforglipron).
  • UBT-251: A triple-pathway drug in development, though it currently lags behind Lilly’s timeline.
• Financials & Valuation:
  • P/E Ratio: Trading at a very low 9.8x.
  • Revenue/EBITDA: Trading at 3x revenue and 6x EBITDA.
  • Dividend: Offers a 4% dividend yield.
  • Margins: Boasts a high 53% EBITDA margin.
• Strategy: Investing heavily in CAPEX and manufacturing (notably in the U.S.) to shift from a high-margin/low-volume model to a mass-market model as prices eventually drop.

Takeaways

• Risk-Adjusted Better Buy: Due to the massive valuation gap (Novo is roughly 4x cheaper on an EV/Revenue basis), it is argued to be the better value for investors.
• Geopolitical Risk: A unique risk factor for NVO is its Danish headquarters. The speaker notes potential "tariff scares" or diplomatic tensions (mentioning Greenland) that could cause the stock to sell off regardless of fundamentals.
• Growth Timing: Novo’s next major growth spurt is expected to happen "a little later" than Lilly’s, once their dual and triple-pathway drugs hit the market.

Eli Lilly (LLY)

Eli Lilly is characterized as the current market leader with superior drug technology, though this leadership comes with a much higher "premium" stock price.

• Product Pipeline:
  • Tirzepatide (Mounjaro/Zepbound): Currently superior to Novo’s Semaglutide in clinical trials because it uses two action pathways.
  • Retatrutide: A "triple pathway" drug (GLP-1/GIP/Glucagon) expected around early 2027. It is highly anticipated on social media and is more advanced in FDA trials than Novo’s triple-pathway competitor.
• Financials & Valuation:
  • Market Cap: Reached the $1 Trillion milestone.
  • Growth: Revenue has tripled in roughly three years, with a projected 24% growth over the next 12 months.
  • Buybacks: Significant buyback program, with potentially $10.9 billion allocated for 2026.
• Innovation: Noted for using NVIDIA data centers and GPU chips to accelerate new drug development.

Takeaways

• The "Quality" Premium: Investors in LLY are paying a higher price for immediate growth and the "best-in-class" current peptide.
• Growth Leader: Lilly’s growth is happening "now," whereas Novo is playing catch-up.
• Valuation Concern: The speaker finds LLY "a little more expensive" and expresses slight concern over the massive buyback program, preferring to see that capital reinvested into the business.

Hims & Hers Health (HIMS)

Mentioned as a secondary way to play the GLP-1 trend.

• Context: HIMS is a platform that sells oral GLP-1 solutions.
• Insight: For investors wanting broad exposure to the sector, the speaker suggests a "basket" approach—buying LLY, NVO, and HIMS—rather than buying specialized GLP-1 ETFs, which the speaker believes are "too spread out" and include lower-quality picks.

Investment Theme: The GLP-1 Sector

The broader weight-loss drug market is viewed as a generational investment opportunity.

• Mass Market Shift: The industry is moving from a niche, expensive treatment ($800/month) to a mass-market commodity ($150–$200/month).
• Adoption Rates: Bullish estimates suggest 1 in 3 Americans could be on a GLP-1 drug by 2030 due to the global obesity epidemic.
• Form Factor: While injections are the current standard, "pill" versions (oral GLP-1s) are expected to see massive adoption from patients who are fearful of needles.
• Strategy Tip: Avoid GLP-1 ETFs if they contain too many "filler" stocks. Direct ownership of the leaders (LLY and NVO) is preferred.